JP2023508011A - 不眠症を治療するためのレンボレキサントの使用 - Google Patents

不眠症を治療するためのレンボレキサントの使用 Download PDF

Info

Publication number
JP2023508011A
JP2023508011A JP2022537669A JP2022537669A JP2023508011A JP 2023508011 A JP2023508011 A JP 2023508011A JP 2022537669 A JP2022537669 A JP 2022537669A JP 2022537669 A JP2022537669 A JP 2022537669A JP 2023508011 A JP2023508011 A JP 2023508011A
Authority
JP
Japan
Prior art keywords
lemborexant
child
pharmaceutically acceptable
acceptable salt
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022537669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023508011A5 (https=
Inventor
アンドリュー サトリン，
マーガレット モリーン，
イシャニ ランドリー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2023508011A publication Critical patent/JP2023508011A/ja
Publication of JP2023508011A5 publication Critical patent/JP2023508011A5/ja
Priority to JP2025131238A priority Critical patent/JP2025160480A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2022537669A 2019-12-20 2020-12-18 不眠症を治療するためのレンボレキサントの使用 Pending JP2023508011A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025131238A JP2025160480A (ja) 2019-12-20 2025-08-06 不眠症を治療するためのレンボレキサントの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951638P 2019-12-20 2019-12-20
US62/951,638 2019-12-20
PCT/US2020/065891 WO2021127359A1 (en) 2019-12-20 2020-12-18 Use of lemborexant for treating insomnia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025131238A Division JP2025160480A (ja) 2019-12-20 2025-08-06 不眠症を治療するためのレンボレキサントの使用

Publications (2)

Publication Number Publication Date
JP2023508011A true JP2023508011A (ja) 2023-02-28
JP2023508011A5 JP2023508011A5 (https=) 2023-12-22

Family

ID=74191874

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022537669A Pending JP2023508011A (ja) 2019-12-20 2020-12-18 不眠症を治療するためのレンボレキサントの使用
JP2025131238A Pending JP2025160480A (ja) 2019-12-20 2025-08-06 不眠症を治療するためのレンボレキサントの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025131238A Pending JP2025160480A (ja) 2019-12-20 2025-08-06 不眠症を治療するためのレンボレキサントの使用

Country Status (11)

Country Link
US (1) US20230051268A1 (https=)
EP (1) EP4076463A1 (https=)
JP (2) JP2023508011A (https=)
KR (1) KR20220119065A (https=)
CN (1) CN115003305A (https=)
AU (1) AU2020408557A1 (https=)
BR (1) BR112022012246A2 (https=)
CA (1) CA3165481A1 (https=)
MX (1) MX2022007304A (https=)
TW (1) TW202137986A (https=)
WO (1) WO2021127359A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024305901A1 (en) * 2023-06-29 2026-02-12 Janssen Pharmaceutica Nv Method of treating depression using seltorexant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018140093A1 (en) * 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0828751A4 (en) 1995-05-05 1999-01-20 Human Genome Sciences Inc HUMAN NEUROPEPTIDE RECEPTOR
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
AU2011304285B2 (en) 2010-09-22 2015-01-29 Eisai R&D Management Co., Ltd. Cyclopropane compound
BR112014019909B1 (pt) 2012-02-17 2020-01-28 Eisai R&D Man Co Ltd processo para produção de compostos úteis como antagonistas do receptor de orexina-2
ES2843952T3 (es) 2014-10-23 2021-07-21 Eisai R&D Man Co Ltd Composiciones para tratar el insomnio

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018140093A1 (en) * 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAYAL, S., ET AL., CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. Vol.105 Supplement S1, JPN6024052274, March 2019 (2019-03-01), pages 54 - 043, ISSN: 0005587168 *
JOURNAL OF CLINICAL SLEEP MEDICINE, vol. 13, no. 11, JPN6025017477, 2017, pages 1289 - 1299, ISSN: 0005587170 *
ＮＥＷＳ ＲＥＬＥＡＳＥ 不眠障害治療薬「レンボレキサント」、日本において新薬承認申請書を提出, JPN6025017475, 2019, JP, ISSN: 0005587169 *
SLEEP, vol. Vol.41,Issue suppl_1, JPN6025017476, 2018, pages 157, ISSN: 0005587171 *

Also Published As

Publication number Publication date
CN115003305A (zh) 2022-09-02
BR112022012246A2 (pt) 2022-08-30
JP2025160480A (ja) 2025-10-22
EP4076463A1 (en) 2022-10-26
TW202137986A (zh) 2021-10-16
CA3165481A1 (en) 2021-06-24
WO2021127359A1 (en) 2021-06-24
KR20220119065A (ko) 2022-08-26
MX2022007304A (es) 2022-08-22
AU2020408557A1 (en) 2022-08-11
US20230051268A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
KR101607081B1 (ko) 디피피-4 저해약과 다른 당뇨병 치료약과의 병용 또는 조합으로 이루어지는 의약
JP6251321B2 (ja) Ｄｇａｔ１阻害剤の使用
RU2703297C2 (ru) Композиции и способы для лечения бессонницы
CN110799181A (zh) 用于治疗睡眠呼吸暂停的方法和组合物
AU2014249534B2 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
EA036103B1 (ru) Способы лечения субъектов с синдромом прадера-вилли или синдромом смита-магениса
CN119523985A (zh) 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用
JP2015537009A (ja) 痛風の治療におけるブシラミンの使用
CN111918655B (zh) 治疗患有慢性肾脏疾病的糖尿病受试者的方法
JP2024523945A (ja) 血糖値の管理方法ならびに糖尿病及び関連状態の治療
JP2025160480A (ja) 不眠症を治療するためのレンボレキサントの使用
WO2024223740A1 (en) Treating psoriasis using a small molecule inhibitor of tumor necrosis factor alpha
TW200843741A (en) Pharmaceutical composition
AU2026201519A1 (en) Lemborexant for treating sleep issues
TW201540300A (zh) 慢性腎臟病之進展抑制或改善用製劑
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
CN104582701A (zh) 减轻体重的方法
JP2019112472A (ja) 網膜症治療剤
KR20080028415A (ko) ＰＰＡＲγ 애고니스트를 함유하는 의약 조성물
CN101217960A (zh) 用于改善尿毒症的治疗药和处置方法
RU2844395C2 (ru) Лемборексант для лечения проблем со сном
KR20190074746A (ko) 시클로-히스프로를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약제학적 제제
WO2025194118A1 (en) Formulations and methods for alleviating sleep disorders
WO2026052068A1 (zh) 药物组合物的用途
Patil et al. Pharmaceutical Interactions in Drug Practices

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250507